Tango Therapeutics (TNGX) Accumulated Expenses (2020 - 2026)

Tango Therapeutics' Accumulated Expenses history runs 7 years deep, the most recent figure standing at $3.2 million for Q1 2026.

• In Q1 2026, Accumulated Expenses rose 1.86% year-over-year to $3.2 million; the TTM figure through Mar 2026 stood at $3.2 million (up 1.86% YoY), while the FY2025 annual figure was $17.8 million, up 98.4% from the prior year.
• Accumulated Expenses was $3.2 million for Q1 2026 at Tango Therapeutics, down from $17.8 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $17.8 million in Q4 2025 to a low of $2.0 million in Q1 2023.
• Historically, Accumulated Expenses has averaged $10.7 million across 5 years, with a median of $11.5 million in 2025.
• The sharpest annual moves came in 2022 and 2023: Accumulated Expenses jumped 4736.23% in 2022, then plunged 78.95% in 2023.
• A 5-year view of Accumulated Expenses shows it stood at $17.5 million in 2022, then dropped by 11.97% to $15.4 million in 2023, then tumbled by 41.88% to $9.0 million in 2024, then soared by 98.4% to $17.8 million in 2025, then slumped by 81.76% to $3.2 million in 2026.
• The last three Accumulated Expenses figures came in at $3.2 million (Q1 2026), $17.8 million (Q4 2025), and $13.1 million (Q3 2025), per Business Quant data.